aBLA Filing Intelligence & Biosimilar Opportunity

Spevigo

Spesolimab-Sbzo

Immunomodulators

Intravenous Injectable

Approval Date

01-Sep-22

Data Exclusivity Expiry

01-Sep-26

Market Exclusivity Expiry

01-Sep-34

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

118

2028

361

2029

703

2030

978

2031

1121

2032

1117

Molecule profile

Details & specifications

Molecule

Spesolimab-Sbzo

Innovator

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

Dosage Form

Intravenous Injectable

Strength

900 mg

Therapeutic Category

Immunomodulators

Usage

To treat generalized pustular psoriasis flares

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.